Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Antidepressant Safety Concerns Depress Zoloft; Forest, Wyeth Still Happy

Executive Summary

Pfizer's Zoloft may feel the greatest negative performance impact from FDA's decision to require a class-wide black box warning for antidepressants

You may also be interested in...



Antidepressant Relabeling Will Include Pediatric Efficacy Data

FDA's plan for relabeling antidepressants to address pediatric safety concerns will involve some negotiation with sponsors over how best to present efficacy data

Antidepressant Relabeling Will Include Pediatric Efficacy Data

FDA's plan for relabeling antidepressants to address pediatric safety concerns will involve some negotiation with sponsors over how best to present efficacy data

Antidepressant “Black Box” Presents Barrier To DTC Advertising

FDA's proposed "black box" warning for all antidepressants would likely mean an end to television ads for the products

Related Content

UsernamePublicRestriction

Register

PS044852

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel